Regulatory Q&A Forum

Ask questions, share knowledge, and get help from the regulatory community

With international consensus standards for biocompatibility undergoing periodic updates, how can manufacturers strategically assess the impact of these changes on both new and existing medical devices...

💬 1 👁️ 13 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

With international consensus standards for biocompatibility undergoing periodic and significant updates, how should manufacturers strategically re-evaluate their biological safety approach for existin...

💬 1 ✓ 👁️ 22 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

Determining the required biocompatibility testing for an FDA 510(k) submission is not a fixed checklist but a risk-based process tailored to the specific medical device. How can sponsors construct a r...

💬 1 👁️ 27 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

Given industry discussions around a potential new global biocompatibility standard emerging by 2026, how can medical device manufacturers proactively prepare their strategies and documentation to avoi...

💬 1 👁️ 29 👍 0
Asked: 3 months ago
Asked by Lo H. Khamis

With the European Chemicals Agency (ECHA) moving towards significant restrictions on per- and polyfluoroalkyl substances (PFAS) under REACH, non-EU manufacturers face a critical compliance challenge. ...

💬 1 ✓ 👁️ 20 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

Given the increasing regulatory focus on per- and polyfluoroalkyl substances (PFAS) under REACH, particularly with the development of a universal restriction proposal, how should a non-EU manufacturer...

💬 1 👁️ 13 👍 0
Asked: 3 months ago
Asked by Lo H. Khamis

What factors determine the scope of services and responsibilities for a REACH Only Representative? For non-EU manufacturers of chemical substances, appointing a REACH Only Representative (OR) is a cr...

💬 1 ✓ 👁️ 32 👍 2
Asked: 3 months ago
Asked by Lo H. Khamis

For a sponsor developing a novel, complex Software as a Medical Device (SaMD) intended for pharmacogenetic assessment, what are the key intersecting regulatory requirements that must be addressed in a...

💬 1 👁️ 25 👍 2
Asked: 3 months ago
Asked by Lo H. Khamis

For non-EU medical device manufacturers, selecting an EU Authorized Representative (AR) under the Medical Device Regulation (MDR) is a critical compliance decision that extends far beyond a simple adm...

💬 1 👁️ 19 👍 2
Asked: 3 months ago
Asked by Lo H. Khamis

When planning for European market entry, non-EU medical device manufacturers often focus on commercial logistics, including the appointment of a VAT Fiscal Representative. However, a distinct and crit...

💬 1 ✓ 👁️ 47 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

For medical device manufacturers placing products on the EU market, compliance with the Waste Electrical and Electronic Equipment (WEEE) Directive and national Extended Producer Responsibility (EPR) l...

💬 1 👁️ 22 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

With significant updates to the EU's Waste Electrical and Electronic Equipment (WEEE) Directive anticipated around 2026, how should medical device manufacturers strategically evaluate and select an EU...

💬 1 👁️ 18 👍 0
Asked: 3 months ago
Asked by Lo H. Khamis

While manufacturers often ask for a single price for a WEEE/EPR Representative in Germany, the cost is not a flat fee but is influenced by several key factors. What are the primary variables that dete...

💬 1 ✓ 👁️ 31 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

When a major international standard for the biological evaluation of medical devices is updated, how should manufacturers strategically revise their biocompatibility testing programs for both new and ...

💬 1 👁️ 23 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

With significant updates to international biocompatibility consensus standards anticipated, how should medical device manufacturers strategically evaluate and select a testing partner to ensure future...

💬 1 ✓ 👁️ 15 👍 2
Asked: 3 months ago
Asked by Lo H. Khamis

When preparing a 510(k) submission, what does a comprehensive biocompatibility evaluation involve beyond simply selecting tests from a standard? While it is understood that medical devices with direc...

💬 1 ✓ 👁️ 18 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

As the UK's post-Brexit medical device regulatory framework continues to evolve towards a new system, non-UK manufacturers face the critical task of ensuring their UK Responsible Person (UKRP) is prep...

💬 1 ✓ 👁️ 21 👍 2
Asked: 3 months ago
Asked by Lo H. Khamis

For non-UK medical device manufacturers planning for market access, securing a UK Responsible Person (UKRP) is a critical compliance step. As regulatory frameworks evolve, budgeting for this service b...

💬 1 ✓ 👁️ 22 👍 2
Asked: 3 months ago
Asked by Lo H. Khamis

When non-UK based medical device manufacturers seek to place products on the Great Britain market (England, Wales, and Scotland), they must appoint a UK Responsible Person (UKRP). While the cost of UK...

💬 1 👁️ 21 👍 1
Asked: 3 months ago
Asked by Lo H. Khamis

For sponsors developing a novel pharmacogenetic assessment system, what are the key regulatory hurdles and evidence requirements under 21 CFR 862.3364? This regulation identifies such a device as a qu...

💬 1 👁️ 20 👍 0
Asked: 3 months ago
Asked by Lo H. Khamis
Showing page 35 of 54 (1079 total questions)